Gilde Healthcare's buy & build platform RAD-x acquires medical imaging group to initiate European expansion - Gilde Healthcare

Gilde Healthcare’s buy & build platform RAD-x acquires medical imaging group to initiate European expansion

24 January 2017

RAD-x closes its first transaction: IRD SA, a leading Swiss Diagnostic Imaging Centre

RAD-x announced that it has acquired Geneva-based IRD SA, a leading diagnostic imaging provider. The sellers of IRD SA will reinvest part of the proceeds in the RAD-x holding and join the Gilde Healthcare Services II Fund and RAD-x management as shareholders of the group. IRD SA will continue to be managed by its founding doctors and with the help of RAD-x will invest in expanding its diagnostic capacity.

With this transaction, RAD-x kick-starts its growth model and positions itself as a contender in the fast consolidating European diagnostic imaging market. RAD-x’ operational model is focused on delivering high quality diagnostic imaging services to patients throughout Europe and its growth strategy is funded by Gilde Healthcare, a leader in healthcare private equity. RAD-x is in discussion with several other medical imaging and healthcare groups to expands its presence across Europe; by achieving a critical mass quickly, RAD-x will achieve better conditions in procurement for heavy medical equipment.

Martin HARDENS, Co-founder and CEO of RAD-x:

“I am pleased that we can welcome new partners in this early stage of development of RAD-x. This acquisition initiates our presence in the Swiss diagnostic imaging market. I look forward to working with the management team of IRD in delivering better healthcare for patients.”

Jasper van GORP, managing partner of Gilde Healthcare Services:

“RAD-x is a fast-growing leader with a first-class management team. In a consolidating market, Gilde has been impressed by RAD-x’ commitment to quality and efficiency towards patients and clinicians. We are confident in its capacity to achieve outstanding growth in RAD-x’ core international markets.”

Frank KOLO, Co-founder and Medical Director of IRD SA:

“I am confident that joining RAD-x will open new growth opportunities for IRD. Having a strong partner enables us to expand the diagnostic services we provide to our patients and referring doctors. RAD-x’ support for IRD to invest in two new state of the art MRI-machines and a refurbishment of our most important site is a proof of our joined commitment to continuous improvement in quality of care.”

 


Contacts:

Jasper van Gorp
Managing Partner
Gilde Healthcare
Tel. +31.30.219.2565
www.gildehealthcare.com

About RAD-x

RAD-x is a pan-European diagnostic imaging platform at the forefront of the outpatient radiology market consolidation in France, Germany and Switzerland. RAD-x’ management team has many years of experience executing radiology and laboratory Buy & Builds. RAD-x’ imaging centers are managed by independent healthcare professionals, all being partners of the group and using shared services to continuously improve their market leading quality and efficiency.
www.rad-x.eu

About Gilde Healthcare

Gilde Healthcare is a specialized European healthcare investor managing two business lines: lower mid-market buy-out funds (Gilde Healthcare Services) and venture & growth capital funds. The Gilde Healthcare Services Funds invest in profitable European healthcare services companies with a focus on the Netherlands, Belgium and Germany. Gilde’s venture & growth capital funds invest in medtech, diagnostics, digital health and therapeutics. Since 2001 Gilde Healthcare has raised €800 million ($900 million) for its specialized funds.
www.gildehealthcare.com

Gilde Healthcare Private Equity as part of Investor Consortium acquires DETAX

Specialist for medical polymer materials DETAX resolves ownership succession in the course of a management buy-out and continues its successful growth track together with a strong Investor Consortium DETAX is a leading global supplier of...
3 December 2021

Adcendo Further Strengthens Management Team and Scientific Advisory Board with Appointment of International ADC Leaders

Building the team with experienced biotech experts and renowned leaders in the ADC field Underscores company’s commitment to progressing lead program on novel ADC target uPARAP Adcendo, a biotech company focused on the development of...
1 December 2021

Gilde Healthcare company Sanifit acquired by Vifor Pharma

Vifor Pharma to acquire Sanifit, a clinical-stage cardio-renal biopharmaceutical company focused on treatments for progressive vascular calcification disorders, complementing and strengthening the Group’s growing nephrology portfolio Sanifit’s lead compound, SNF472 is a novel, first-in-class inhibitor...
22 November 2021